Lloyd-JonesD, AdamsRJ, BrownTM, Executive summary: Heart disease and stroke statistics—2010 update: A report from the American Heart Association. Circulation. 2010;121:948–954
2.
LeiriaTLL, LopesRD, WilliamsJB, Antithrombotic therapies in patients with prosthetic heart valves: Guidelines translated for the clinician. J Thromb Thrombolysis. 2011;31:514–522.
3.
EllisCR, KaiserDW. The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Vasc Health Risk Manag. 2013;9:341–362.
4.
ConnollySJ, EzekowitzMD, YusufS, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009;361(12):1139–1151. [Erratum published in N Engl J Med. 2010;363(19):1877].
5.
YouJJ, SingerDE, HowardPA, Antithrombotic therapy for atrial fibrillation antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl): e531S–575S.
6.
McKellarSH, AbelS, CampCLEffectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141:1410–1416.
7.
SchomburgJL, MedinaEM, Lahti MT Bianco RW. Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. J Invest Surg. 2012;25:150–155.
8.
AtarS, WishniakA, ShturmanA, Fatal association of mechanical valve thrombosis with dabigatran. Chest. 2013;144:327–328.
9.
StewartRA, AstellH, YoungL, WhiteHD. Thrombosis on a mechanical aortic valve whilst anti-coagulated with dabigatran. Heart Lung Circ. 2012;21:53–55.
10.
PriceJ, HynesM, LabinazM, RuelM, BoodhwaniM.Mechanical valve thrombosis on dabigatran. J Am Coll Cardiol. 2012;60.1710–1711.
11.
EikelboomJW, ConnollySJ, BrueckmannM, ; for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–1214.
12.
HylekEM. Dabigatran and mechanical heart valves – not as easy as we hoped. N Engl J Med. 2013;369:1264–1266.
13.
Drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. Silver Spring, MD: Food and Drug Administration; December 19, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm. Accessed November 7, 2013.
14.
CannegieterSC, RosendaalFR, BrietE.Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635–641.
15.
Pradaxa [product information]. Ridgefield, CT: Boehringer Ingelheim. Revised December 2013.
16.
WhitlockRP, SunJC, FremesSE, Antithrombotic and thrombolytic therapy for valvular disease. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl): e576S–e600S.
17.
BonowRO, CarabelloBA, ChatterjeeK, 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;52:e1–e142.
